Jump to content

Antidepressant discontinuation syndrome

From Wikipedia, the free encyclopedia
Not to be confused with Serotonin syndrome.

Antidepressant discontinuation syndrome
Other namesAntidepressant withdrawal syndrome[1]
SpecialtyPsychiatry
SymptomsFlu-like symptoms, trouble sleeping, anxiety, depression, dissociation, intrusive thoughts, nausea, poor balance, sensory changes[2]
Usual onsetWithin 3 days[2]
DurationFew weeks to months[3][4]
CausesStopping of an antidepressant medication[2][3]
Diagnostic methodBased on symptoms[2]
Differential diagnosisAnxiety, mania, stroke[2]
PreventionGradual dose reduction[2]
Frequency15–50% (with sudden stopping)[3][4]

Antidepressant discontinuation syndrome, also called antidepressant withdrawal syndrome, is a condition that can occur following the interruption, reduction, or discontinuation of antidepressant medication following its continuous use of at least a month.[5] The symptoms may include flu-like symptoms, trouble sleeping, nausea, poor balance, sensory changes, akathisia, intrusive thoughts, depersonalization and derealization, mania, anxiety, and depression.[2][3][4] The problem usually begins within three days[2] and may last for several weeks or months.[4] Psychosis may rarely occur.[2]

A discontinuation syndrome can occur after stopping any antidepressant including selective serotonin reuptake inhibitors (SSRIs), serotonin–norepinephrine reuptake inhibitors (SNRIs), monoamine oxidase inhibitors (MAOIs), and tricyclic antidepressants (TCAs).[2][3] The risk is greater among those who have taken the medication for longer and when the medication in question has a short half-life.[2] The underlying reason for its occurrence is unclear.[2] The diagnosis is based on the symptoms.[2]

Methods of prevention include gradually decreasing the dose among those who wish to stop, though it is possible for symptoms to occur with tapering.[2][6][4] Treatment may include restarting the medication and slowly decreasing the dose.[2] People may also be switched to the long-acting antidepressant fluoxetine which can then be gradually decreased.[6]

Approximately 15–50% of people who suddenly stop an antidepressant develop antidepressant discontinuation syndrome.[7][2][3][4] The condition is generally not serious,[2] though about half of people with symptoms describe them as severe.[4] Many restart antidepressants due to the severity of the symptoms.[4]

Antidepressant discontinuation syndrome is a relatively new phenomenon, being identified and described from 1950s onwards, in parallel with discovery and introduction of modern antidepressant medications, with the first MAOIs, and TCAs introduced from the 1950s onwards and the first SSRIs from the 1980s onwards.[8] There is still little research on this syndrome; most of the research is conflicting or consists only of clinical trials.[9]

Signs and symptoms

[edit]

People with antidepressant discontinuation syndrome have been on an antidepressant for at least four weeks and have recently stopped taking the medication, whether abruptly, after a fast taper, or each time the medication is reduced on a slow taper.[2] Commonly reported symptoms include flu-like symptoms (e.g., nausea, vomiting, diarrhea, headaches, sweating) and sleep disturbances (e.g., insomnia, nightmares, constant sleepiness). Sensory and movement disturbances have also been reported, including imbalance, tremors, vertigo, dizziness, and electric-shock-like experiences in the brain, often described by people who have them as brain zaps. These "brain zaps" have been described as an electric shock felt in the skull, potentially triggered by lateral eye movement, and at times accompanied by vertigo, pain, or dissociative symptoms. Some individuals consider it as a pleasant experience akin to an orgasm, however it is more often reported as an unpleasant experience that interferes with daily function.[10] Mood disturbances such as dysphoria, anxiety, or agitation are also reported, as are cognitive disturbances such as confusion and hyperarousal. In cases associated with sudden discontinuation of MAO inhibitors (MAOIs), acute psychosis has been observed.[2][11][12] Over fifty symptoms have been reported.[13] The SNRI venlafaxine has been reported to have a higher incidence in withdrawal symptoms after discontinuation when compared to other SNRIs.[14] Venlafaxine has also been implicated to create withdrawal symptoms regardless of dosage.[15] Venlafaxine has been implicated in causing the most severe withdrawal symptoms after cessation of use, possibly due to its short half-life.[16]

To simplify identifying the principal signs and symptoms, the mnemonic FINISH may be used:

  • Flu-like symptoms
  • Insomnia
  • Nausea
  • Imbalance
  • Sensory disturbances, including "brain zaps"
  • Hyperarousal[17][18]

A 2009 Advisory Committee to the U.S. Food and Drug Administration found that online anecdotal reports of discontinuation syndrome related to duloxetine included severe symptoms and exceeded prevalence of both paroxetine and venlafaxine reports by over 250% (although acknowledged this may have been influenced by duloxetine being a much newer drug).[19] It also found that the safety information provided by the manufacturer not only neglected important information about managing discontinuation syndrome, but also explicitly advised against opening capsules, a practice required to gradually taper dosage.[19]

Duration

[edit]

Most cases of discontinuation syndrome may last between one and four weeks and resolve on their own.[2] Occasionally symptoms can last up to one year.[3] They typically resolve within a day of restoring the medication.[20] Paroxetine and venlafaxine seem to be particularly difficult to discontinue, and prolonged withdrawal syndrome (post-acute-withdrawal syndrome, or PAWS) lasting over 18 months has been reported with paroxetine.[21][22][23]

Mechanism

[edit]

The underlying reason for its occurrence is unclear,[2][12] though the syndrome appears similar to withdrawal from other psychotropic drugs such as benzodiazepines.[1] For SSRIs, a tapered discontinuation results in less severe symptoms. There is also evidence that antidepressant discontinuation syndrome may be related to the biological half-life of both SSRIs[24] and antidepressants in general. Antidepressants with a lower half-life, such as paroxetine, duloxetine, and venlafaxine, have been implicated in higher incidences of withdrawal symptoms and more severe withdrawal symptoms.[25] With SSRIs, duration of treatment does not appear associated with the severity of withdrawal symptoms.[24]

One hypothesis is that after the antidepressant is discontinued, there is a temporary (but in some cases long-lasting) deficiency in the brain of one or more essential neurotransmitters that regulate mood, such as serotonin, dopamine, norepinephrine, and gamma-aminobutyric acid, and since neurotransmitters are an interrelated system, dysregulation of one affects the others.[2][26] There may be a link between lower 5-hydroxytryptamine (5-HT, i.e. serotonin) receptor availability and symptoms of antidepressant discontinuation syndrome.[24][27]

Research

[edit]

Animal models are able to recapitulate some aspects of antidepressant withdrawal. For example, discontinuation of paroxetine in mice leads to anxiety-like behavior, together with a rebound over-activation of 5-HT neurons.[28] One problem is that many animal studies use fluoxetine as the study drug, despite it being not very commonly associated with withdrawal in human patients. A lack of understanding over how antidepressants work also complicates the picture. More studies using more relevant drugs, along with measuring more relevant aspects of the nervous system, will be needed to understand the mechanism of withdrawal in rodents.[24]

Prevention and treatment

[edit]

In some cases, withdrawal symptoms may be prevented by taking medication as directed, and when discontinuing, doing so gradually, although symptoms may appear while tapering. When discontinuing an antidepressant with a short half-life, switching to a drug with a longer half-life (e.g., fluoxetine or citalopram) and then tapering, and eventually discontinuing, from that drug can decrease the severity of symptoms in some cases.[11]

Treatment is dependent on the severity of the discontinuation reaction and whether or not further antidepressant treatment is warranted. In cases where further antidepressant treatment is prescribed, then the only option suggested may be restarting the antidepressant. If antidepressants are no longer required, treatment depends on symptom severity. If symptoms of discontinuation are severe, or do not respond to symptom management, the antidepressant can be reinstated and then withdrawn more cautiously, or by switching to a drug with a longer half life (e.g., fluoxetine), and then tapering and discontinuing that drug.[21] In severe cases, hospitalization may be required.[2]

Pregnancy and newborns

[edit]

Antidepressants, including SSRIs, can cross the placenta and have the potential to affect the fetus and newborn, including an increased chance of miscarriage, presenting a dilemma for pregnant women to decide whether to continue to take antidepressants at all, or if they do, considering if tapering and discontinuing during pregnancy could have a protective effect for the newborn.[29]

Neonatal withdrawal syndrome was first noticed in 1973 in newborns of mothers taking antidepressants; symptoms in the infant include irritability, rapid breathing, hypothermia, and blood sugar problems. The symptoms usually develop from birth to days after delivery and usually resolve within days or weeks of delivery.[29]

Culture and history

[edit]

Antidepressant discontinuation symptoms were first reported with imipramine, the first tricyclic antidepressant (TCA), in the late 1950s, and each new class of antidepressants has brought reports of similar conditions, including monoamine oxidase inhibitors (MAOIs), SSRIs, and SNRIs. As of 2001, at least 21 different antidepressants, covering all the major classes, were known to cause discontinuation syndromes.[21] The problem has been poorly studied, and most of the literature has been case reports or small clinical studies; incidence is hard to determine and controversial.[21]

With the explosion of use and interest in SSRIs in the late 1980s and early 1990s, focused especially on Prozac, interest grew as well in discontinuation syndromes.[30] Some of the symptoms emerged from discussion boards where people with depression discussed their experiences with the disease and their medications; "brain zaps" or "brain shivers" was one symptom that emerged via these websites.[31][32]

Heightened media attention and continuing public concerns led to the formation of an expert group on the safety of SSRIs in England to evaluate all the research available prior to 2004.[33]: iv  The group determined that the incidence of discontinuation symptoms are between 5% and 49%, depending on the particular SSRI, the length of time on the medicine and abrupt versus gradual cessation.[33]: 126–136 

With the lack of a definition based on consensus criteria for the syndrome, a panel met in Phoenix, Arizona, in 1997 to form a draft definition,[34] which other groups continued to refine.[35][36]

In the late 1990s, some investigators thought that the fact that symptoms emerged when antidepressants were discontinued might mean that antidepressants were causing addiction, and some used the term "withdrawal syndrome" to describe the symptoms. While people taking antidepressants do not commonly exhibit drug-seeking behavior, stopping antidepressants leads to similar symptoms as found in drug withdrawal from benzodiazapines, and other psychotropic drugs.[37][38] As such, some researchers advocate the term withdrawal over discontinuation, to communicate the similar physiological dependence and negative outcomes.[1] Due to pressure from pharmaceutical companies who make antidepressants, the term "withdrawal syndrome" is no longer used by drug makers, and thus, most doctors, due to concerns that they may be compared to other drugs more commonly associated with withdrawal.[2]

2013 class action lawsuit

[edit]

In 2013, a proposed class action lawsuit, Jennifer L Saavedra v. Eli Lilly and Company,[39] was brought against Eli Lilly claiming that the Cymbalta label omitted important information about "brain zaps" and other symptoms upon cessation.[40] Eli Lilly moved for dismissal per the "learned intermediary doctrine" as the doctors prescribing the drug were warned of the potential problems and are an intermediary medical judgment between Lilly and patients; in December 2013, Lilly's motion to dismiss was denied. In December 2014, class certification was denied. A second attempt at certification in 2015 also failed.[41]

See also

[edit]

References

[edit]
  1. ^ a b c "Antidepressant Withdrawal Syndrome". ubc.ca. Therapeutics Initiative, The University of British Columbia. 23 July 2018. Retrieved 3 August 2018.
  2. ^ a b c d e f g h i j k l m n o p q r s t u v w x Warner CH, Bobo W, Warner C, Reid S, Rachal J (1 August 2006). "Antidepressant discontinuation syndrome". American Family Physician. 74 (3): 449–56. PMID 16913164.
  3. ^ a b c d e f g Gabriel M, Sharma V (29 May 2017). "Antidepressant discontinuation syndrome". Canadian Medical Association Journal. 189 (21): E747. doi:10.1503/cmaj.160991. PMC 5449237. PMID 28554948.
  4. ^ a b c d e f g h Davies J, Read J (4 September 2018). "A systematic review into the incidence, severity and duration of antidepressant withdrawal effects: Are guidelines evidence-based?". Addictive Behaviors. 97: 111–121. doi:10.1016/j.addbeh.2018.08.027. PMID 30292574.
  5. ^ Diagnostic and statistical manual of mental disorders: DSM-5 (5th ed.). American Psychiatric Association. 2013. pp. 712–714. ISBN 9780890425541.
  6. ^ a b Wilson E, Lader M (December 2015). "A review of the management of antidepressant discontinuation symptoms". Therapeutic Advances in Psychopharmacology. 5 (6): 357–68. doi:10.1177/2045125315612334. PMC 4722507. PMID 26834969.
  7. ^ Henssler, J.; Schmidt, Y.; Schmidt, U.; Schwarzer, G.; Bschor, T.; Baethge, C. (2024). "Incidence of antidepressant discontinuation symptoms: a systematic review and meta-analysis". The Lancet Psychiatry. doi:10.1016/S2215-0366(24)00133-0.
  8. ^ Healy D (2001). "The Antidepressant Drama". In Weissman MM (ed.). The treatment of depression: bridging the 21st century. American Psychiatric Pub. ISBN 978-0-88048-397-1.
  9. ^ Johnston JA, Nelson DR, Bhatnagar P, Curtis SE, Chen Y, MacKrell JG (2021-02-23). "Prevalence and cardiometabolic correlates of ketohexokinase gene variants among UK Biobank participants". PLOS ONE. 16 (2): e0247683. Bibcode:2021PLoSO..1647683J. doi:10.1371/journal.pone.0247683. ISSN 1932-6203. PMC 7901775. PMID 33621267.
  10. ^ Papp A, Onton JA (2018-12-20). "Brain Zaps: An Underappreciated Symptom of Antidepressant Discontinuation". The Primary Care Companion for CNS Disorders. 20 (6). doi:10.4088/PCC.18m02311. ISSN 2155-7780. PMID 30605268. S2CID 58577252.
  11. ^ a b Haddad PM, Anderson IM (October 2007). "Recognising and managing antidepressant discontinuation symptoms". Advances in Psychiatric Treatment. 13 (6): 447–57. doi:10.1192/apt.bp.105.001966.
  12. ^ a b Renoir T (2013). "Selective serotonin reuptake inhibitor antidepressant treatment discontinuation syndrome: a review of the clinical evidence and the possible mechanisms involved". Front Pharmacol. 4: 45. doi:10.3389/fphar.2013.00045. PMC 3627130. PMID 23596418.
  13. ^ Haddad PM, Dursun SM (2008). "Neurological complications of psychiatric drugs: clinical features and management". Hum Psychopharmacol. 23 (Suppl 1): 15–26. doi:10.1002/hup.918. PMID 18098217.
  14. ^ Fava GA, Benasi G, Lucente M, Offidani E, Cosci F, Guidi J (2018). "Withdrawal Symptoms after Serotonin-Noradrenaline Reuptake Inhibitor Discontinuation: Systematic Review". Psychotherapy and Psychosomatics. 87 (4): 195–203. doi:10.1159/000491524. ISSN 1423-0348. PMID 30016772.
  15. ^ Wang J, Greenberg H (2013-07-15). "Status Cataplecticus Precipitated by Abrupt Withdrawal of Venlafaxine". Journal of Clinical Sleep Medicine. 09 (7): 715–716. doi:10.5664/jcsm.2848. ISSN 1550-9389. PMC 3671338. PMID 23853567.
  16. ^ Khan AM (October 2020). "27.3 The Effectiveness of SSRIs for Treatment of OCD in Children and Adolescents: A Systematic Review and Meta-Analysis". Journal of the American Academy of Child & Adolescent Psychiatry. 59 (10): S202. doi:10.1016/j.jaac.2020.09.006. ISSN 0890-8567.
  17. ^ Rizcalla M, Kowalkovski B, Prozialeck WA (2020-02-20). "Antidepressant Discontinuation Syndrome: A Common but Underappreciated Clinical Problem". Journal of Osteopathic Medicine. 120 (3): 174–178. doi:10.7556/jaoa.2020.030. PMID 32077900.
  18. ^ Bhat V, Kennedy S (2017-07-01). "Recognition and management of antidepressant discontinuation syndrome". Journal of Psychiatry & Neuroscience. 42 (4): E7–E8. doi:10.1503/jpn.170022. PMC 5487275. PMID 28639936.
  19. ^ a b "Cymbalta (Duloxetine) Discontinuation Syndrome: Issues of Scope, Severity, Duration & Management" (PDF). U.S. Food and Drug Administration (FDA). 9 June 2009. Retrieved 17 October 2016.
  20. ^ Haddad PM, Anderson IM (1 November 2007). "Recognising and managing antidepressant discontinuation symptoms". Advances in Psychiatric Treatment. 13 (6): 447–457. doi:10.1192/apt.bp.105.001966. ISSN 2056-4678.
  21. ^ a b c d Haddad PM (March 2001). "Antidepressant discontinuation syndromes". Drug Safety. 24 (3): 183–97. doi:10.2165/00002018-200124030-00003. PMID 11347722. S2CID 26897797.
  22. ^ Tamam L, Ozpoyraz N (January–February 2002). "Selective Serotonin Reuptake Inhibitor Discontinuation Syndrome: A Review". Advances in Therapy. 19 (1): 17–26. doi:10.1007/BF02850015. PMID 12008858. S2CID 5563223.
  23. ^ Gartlehner G, Hansen RA, Morgan LC, et al. (December 2011). "Results". Second-Generation Antidepressants in the Pharmacologic Treatment of Adult Depression: An Update of the 2007 Comparative Effectiveness Review (Report). Comparative Effectiveness Reviews. Rockville, MD: Agency for Healthcare Research and Quality.
  24. ^ a b c d Renoir T (2013). "Selective serotonin reuptake inhibitor antidepressant treatment discontinuation syndrome: a review of the clinical evidence and the possible mechanisms involved". Frontiers in Pharmacology. 4: 45. doi:10.3389/fphar.2013.00045. ISSN 1663-9812. PMC 3627130. PMID 23596418.
  25. ^ Gastaldon C, Schoretsanitis G, Arzenton E, Raschi E, Papola D, Ostuzzi G, Moretti U, Seifritz E, Kane JM, Trifirò G, Barbui C (December 2022). "Withdrawal Syndrome Following Discontinuation of 28 Antidepressants: Pharmacovigilance Analysis of 31,688 Reports from the WHO Spontaneous Reporting Database". Drug Safety. 45 (12): 1539–1549. doi:10.1007/s40264-022-01246-4. ISSN 1179-1942. PMC 9676852. PMID 36400895.
  26. ^ Damsa, C., Bumb, A., Bianchi-Demicheli, F., et al. (August 2004). "'Dopamine-dependent' side effects of selective serotonin reuptake inhibitors: a clinical review". J Clin Psychiatry. 65 (8): 1064–8. doi:10.4088/JCP.v65n0806. PMID 15323590.
  27. ^ Blier P, Tremblay P (2006). "Physiologic mechanisms underlying the antidepressant discontinuation syndrome". The Journal of Clinical Psychiatry. 67 (Suppl 4): 8–13. ISSN 0160-6689. PMID 16683857.
  28. ^ Collins HM, Gullino LS, Ozdemir D, Lazarenco C, Sudarikova Y, Daly E, Pilar Cuéllar F, Pinacho R, Bannerman DM, Sharp T (September 2024). "Rebound activation of 5-HT neurons following SSRI discontinuation". Neuropsychopharmacology. 49 (10): 1580–1589. doi:10.1038/s41386-024-01857-8. hdl:10902/32997. PMC 11319583. PMID 38609530.
  29. ^ a b Byatt N, Deligiannidis KM, Freeman MP (Feb 2013). "Antidepressant use in pregnancy: a critical review focused on risks and controversies". Acta Psychiatr Scand. 127 (2): 94–114. doi:10.1111/acps.12042. PMC 4006272. PMID 23240634.
  30. ^ Stutz B (2007-05-06). "Self-Nonmedication". New York Times. Retrieved 2010-05-24.
  31. ^ Christmas, M.B. (2005). "'Brain shivers': from chat room to clinic". Psychiatric Bulletin. 29 (6): 219–21. doi:10.1192/pb.29.6.219.
  32. ^ Aronson J (8 October 2005). "Bottled lightning". BMJ. 331 (7520): 824. doi:10.1136/bmj.331.7520.824. PMC 1246084.
  33. ^ a b Expert Group on the Safety of Selective Serotonin Reuptake Inhibitors (SSRIs) (December 2004). Weller IV (ed.). "Report of the CSM Expert Working Group on the Safety of Selective Serotonin Reuptake Inhibitor Antidepressants" (PDF). Medicines and Healthcare Products Regulatory Agency. Retrieved 1 August 2014.
  34. ^ Schatzberg, A.F., Haddad, P., Kaplan, E.M., Lejoyeux, M., Rosenbaum, J.F., Young, A.H., Zajecka, J. (1997). "Serotonin reuptake inhibitor discontinuation syndrome: a hypothetical definition. Discontinuation Consensus panel". J Clin Psychiatry. 5u (7): 5–10. PMID 9219487. Archived from the original on 2024-02-22.
  35. ^ Black, K., Shea, C., Dursun, S., Kutcher, S. (2000). "Selective serotonin reuptake inhibitor discontinuation syndrome: proposed diagnostic criteria". J Psychiatry Neurosci. 25 (3): 255–61. PMC 1407715. PMID 10863885.
  36. ^ WHO Expert Committee on Drug Dependence – Thirty-third Report / WHO Technical Report Series 915 (Report). World Health Organization. 2003. Archived from the original on August 30, 2009.
  37. ^ Nielsen, M., Hanse, E.H., Gøtzsche, P.C. (2012). "What is the difference between dependence and withdrawal reactions? A comparison of benzodiazepines and selective serotonin re-uptake inhibitors". Addiction. 105 (5): 900–8. doi:10.1111/j.1360-0443.2011.03686.x. PMID 21992148.
  38. ^ Fava, G.A., Gatti, A, Belaise, C., et al. (2015). "Withdrawal Symptoms after Selective Serotonin Reuptake Inhibitor Discontinuation: A Systematic Review". Psychother Psychosom. 84 (2): 72–81. doi:10.1159/000370338. PMID 25721705.
  39. ^ Jennifer L Saavedra v. Eli Lilly and Company – via Justia.com.
  40. ^ Overley J (January 29, 2013). "Lilly Fights Cymbalta 'Brain Zaps' Suit, Saying It Warned Docs". Law360. Retrieved 3 August 2014.
  41. ^ Tushnet R (December 9, 2013). "Learned intermediary doctrine doesn't bar claim at pleading stage". Rebecca Tushnet's 43(B)log.
[edit]
Retrieved from "https://en.wikipedia.org/w/index.php?title=Antidepressant_discontinuation_syndrome&oldid=1264657005"